Successful conversion to belatacept after thrombotic microangiopathy in kidney transplant patients

Sireesha Koppula, Sarah E. Yost, Amy Sussman, Erika R. Bracamonte, Bruce Kaplan

Research output: Contribution to journalArticle

10 Scopus citations

Abstract

Thrombotic microangiopathy (TMA) is a severe complication of kidney transplantation. TMA may occur de novo or as recurrent disease post-transplant. De novo disease is usually associated with immunosuppressive drugs or can be seen as a part of endothelial damage that accompanies antibody-mediated rejection. Treatment for de novo TMA is limited to plasma exchange and change in immunosuppression. We report two cases of de novo TMA post-transplant that were successfully treated by converting to belatacept for maintenance immunosuppression.

Original languageEnglish (US)
Pages (from-to)591-597
Number of pages7
JournalClinical Transplantation
Volume27
Issue number4
DOIs
StatePublished - Jul 1 2013

Keywords

  • Belatacept
  • Renal transplantation
  • Tacrolimus
  • Thrombotic microangiopathy

ASJC Scopus subject areas

  • Transplantation

Fingerprint Dive into the research topics of 'Successful conversion to belatacept after thrombotic microangiopathy in kidney transplant patients'. Together they form a unique fingerprint.

  • Cite this